Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSD17B13 | Q7Z5P4 | 10/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14478207 | 0.85 | HTR2C (0.41) | ALDH1A1HSD17B13 | |
| SCHEMBL13947776 | 0.80 | HSD17B13 (0.43) | HSD17B13 | |
| SCHEMBL24664732 | 0.78 | RGS4 (0.39) | ALDH1A1HSD17B13TSHRHSD17B10L3MBTL1 | |
| SCHEMBL24665500 | 0.78 | HSD17B13 (0.44) | ALDH1A1HSD17B13 | |
| SCHEMBL5487196 | 0.76 | HSD17B13 (0.47) | HSD17B13 | |
| SCHEMBL5610519 | 0.76 | HSD17B13 (0.43) | HSD17B13 | |
| SCHEMBL5407475 | 0.75 | ALDH1A1 (0.35) | ALDH1A1TSHRHSD17B10L3MBTL1POLB | |
| SCHEMBL7595779 | 0.73 | HSD17B13 (0.41) | ALDH1A1HSD17B13TSHRL3MBTL1POLB | |
| SCHEMBL9120735 | 0.72 | HSD17B13 (0.40) | ALDH1A1HSD17B13 | |
| SCHEMBL9118024 | 0.70 | CYP3A4 (0.51) | ALDH1A1HSD17B13SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059665-A1 | DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2022198196-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-9371327-B2 | PDE1 inhibitor compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2367428-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20150353556-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-12-10 | — | — | US | disclosed |
| US-8927556-B2 | 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130324565-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| EP-2590657-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| US-20120136013-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES. INC. | 2012-05-31 | — | — | US | disclosed |
| WO-2011153135-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| EP-2367428-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010065147-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | ALDH1A1 2458/4885HSD17B13 124/4885TSHR 3766/4885 |
| US-20150353556-A1 | ORGANIC COMPOUNDS | CYP2C9, TPMT, CYP2C19 | ALDH1A1 214/4885HSD17B13 1413/4885TSHR 2115/4885 |
| US-20120136013-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A4 | ALDH1A1 216/4885HSD17B13 1296/4885TSHR 2078/4885 |
| US-20130324565-A1 | ORGANIC COMPOUNDS | UGT2B7, CYP2C9, CYP4B1 | ALDH1A1 326/4885HSD17B13 892/4885TSHR 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.